Middle East respiratory syndrome coronavirus (MERS-CoV) was initially isolated from a sputum specimen of a patient who died of respiratory and renal failure in Saudi Arabia in 2012.[@bib1] Recent data have indicated that dromedary camels are likely to transmit MERS-CoV to humans.[@bib2], [@bib3] Human-to-human MERS-CoV transmission is well documented, particularly in the setting of nosocomial outbreaks.[@bib4], [@bib5]

As of July 7, 2015, the World Health Organization (WHO) was notified of 1368 laboratory-confirmed cases of MERS-CoV infection with 487 reported deaths (35.6%) from 26 countries, primarily in men with a median age of 50 years.[@bib6] Most cases (\>75%) were reported from the Kingdom of Saudi Arabia.[@bib6] MERS-CoV infection can result in a wide clinical spectrum from asymptomatic infection, upper respiratory tract illness, to severe pneumonia and multiorgan failure.[@bib7], [@bib8], [@bib9] MERS-CoV binds to dipeptidyl peptidase 4 (DPP4) receptors that are primarily in the lower respiratory tract but also distributed in other tissues.[@bib10] Although there have been numerous cases and fatalities, the pathologic changes and viral distribution in humans associated with severe MERS-CoV illness are unknown, and knowledge of pathogenesis remains limited.

This report provides the first autopsy, clinicopathologic, immunohistochemical (IHC), and ultrastructural description of a fatal case of MERS-CoV. This patient, who had multiple close contacts, was identified as part of an epidemiologic investigation of a large cluster of MERS-CoV infections at hospital in the United Arab Emirates (UAE) in April 2014. This outbreak occurred in the context of a surge of cases in the Arabian Peninsula in which 515 MERS-CoV cases were identified in Saudi Arabia from April 11 to June 9, 2014 (World Health Organization, [*http://www.who.int/csr/don/2014_06_13_mers/en*](http://www.who.int/csr/don/2014_06_13_mers/en){#intref0010}, last accessed October 9, 2015).

Materials and Methods {#sec1}
=====================

Histopathologic and IHC Studies {#sec1.1}
-------------------------------

Tissues obtained at autopsy were fixed in 10% buffered formalin, paraffin-embedded, sectioned at 4 μm, and stained by routine hematoxylin and eosin. An immunostaining protocol was applied with use of several mouse antibodies and one human antibody to MERS-CoV as described previously.[@bib11]

IHC assays that used mouse anti-MERS antibodies ([Table 1](#tbl1){ref-type="table"} ) were performed with the use of a polymer-based indirect immunoalkaline phosphatase detection system with colorimetric detection of antibody/polymer complex with Fast Red Chromogen (Thermo Fisher Scientific, Runcom, Cheshire, UK, or Biocare Medical, Concord, CA). IHC assays with the use of the human, anti--MERS-CoV antibody were performed with the Klear Human AP-Polymer Detection Kit with GBI Permanent Red Chromogen (GBI Labs, Bothell, WA). Double-stained assays used the Envision G/2 Double Stain System, Rabbit/Mouse (DAB + Permanent Red) from Dako (Glostrup, Denmark). Antibodies against CD68 (Dako), cytokeratin (Dako), surfactant apoprotein A (Dako), and DPP4 (Origene Technologies, Rockville, MD), followed by the anti--MERS-CoV antibodies \[CDC (Atlanta, GA) and University of North Carolina (Chapel Hill, NC)\], were used. All assays were performed according to the manufacturer\'s guidelines. MERS-CoV--infected and --noninfected Vero cells and tissues from non--MERS-CoV cases and normal mouse sera in place of primary antibodies were used as positive and negative controls, respectively.Table 1Primary Antibodies Used for IHCAb No.Primary AbHostDilutionPretreatmentAb sourceDetectionComments1510/1513MERS-CoVMouse hyperimmune serum1:200PKCDC, DVD(no. 1253) UVLPMERS-CoV_JordanN31511EMC SMouse hyperimmune serum1:500PKRalph Baric, UNC(no. 1253) UVLP1512HKU5.2 NMouse hyperimmune serum1:500ARCDC, DVD(no. 1253) UVLPBat coronavirus1514γ-Irradiated IN case serumHuman1:1000ARCDC, DVD(no. 1518) Klear0274CD68 (KP1)MAB1:100ARDako(no. 1371) Envision Doublestain0304Cytokeratin (AE1 and AE3)MAB1:100ARDako(no. 1371) Envision Doublestain1037Surfactant apoprotein A (PE10)HMAF1:100ARDako(no. 1371) Envision Doublestain1547DPP4 (clone OTI11D7)MAB1:100PKOrigene Technologies(no. 1371) Envision Doublestain[^1]

Ultrastructural Studies {#sec1.2}
-----------------------

Lung tissue samples were excised from a paraffin block with the use of a 2-mm punch and processed for electron microscopy examination as previously described.[@bib12]

Molecular Analysis {#sec1.3}
------------------

Full genome sequencing by the Sanger method with the use of direct genome walking PCR and next-generation sequencing (Illumina MiSeq; Illumina, San Diego, CA) were performed as previously described on confirmed positive lung tissue,[@bib13] named as Abu Dhabi_UAE_8\_2014 and deposited into GenBank ([*http://www.ncbi.nlm.nih.gov*](http://www.ncbi.nlm.nih.gov){#intref0015}; GenBank accession number KP209306). ClustalW was used to align the full genome with the respective available complete or near complete MERS-CoV genomes in GenBank.[@bib14] Phylogenetic reconstructions were performed with MrBayes version 3.2 (MrBayes: Bayesian Inference of Phylogeny, [*http://mrbayes.sourceforge.net*](http://mrbayes.sourceforge.net){#intref0020}, last accessed June 22, 2015) under a General-Time-Reversible model of nucleotide substitution with four categories of γ-distributed rate heterogeneity and a proportion of invariant sites (GTR + 4 + I).[@bib15]

Results {#sec2}
=======

Clinical History and Findings {#sec2.1}
-----------------------------

The patient was a 45-year-old, nonsmoking, obese (body mass index, 30.5 kg/m^2^) Filipino man with no relevant past medical history, recent travel, or exposure to sick contacts or farm animals. He worked in a storage room at a paramedic station with no patient care duties. He shared housing with five roommates from the paramedic department.

He presented to an emergency department in Abu Dhabi, UAE, on April 2, 2014, with a 4-day history of fever, rhinorrhea, and productive cough. At evaluation, he was afebrile with an oxygen saturation of 99% on room air, and a chest X-ray showed a left-sided opacity ([Figure 1](#fig1){ref-type="fig"} A). The patient was diagnosed as acute bronchitis, prescribed 20 mg prednisolone daily for 5 days and paracetamol, and discharged. He returned to the emergency department on April 6, 2014, with persistent cough and shortness of breath; a chest X-ray showed a left-sided opacity and air bronchograms, and the patient was diagnosed with pneumonia, given a prescription for levofloxacin, and discharged ([Figure 1](#fig1){ref-type="fig"}B). He returned to the emergency department the same day, with worsening shortness of breath and was admitted. He had a temperature of 38.7°C, pulse of 113 beats per minute, a respiratory rate of 24 breaths per minute, blood pressure of 123/73, an oxygen saturation of 93% on room air, and left basal crackles and rales. An arterial blood gas on room air showed pH of 7.49, partial pressure of carbon dioxide of 27.6 mm Hg, partial pressure of oxygen of 52.4 mm Hg, and bicarbonate of 20.7 mEq/L, consistent with respiratory alkalosis. Laboratory evaluation showed a normal white blood cell count with lymphopenia (0.5 K/μL) and creatinine of 0.9 mg/dL ([Supplemental Table S1](#appsec1){ref-type="sec"}). Blood, sputum, and urine cultures were obtained, and a nasopharyngeal swab specimen was sent for MERS-CoV testing. On April 7, day 1 of admission, oseltamivir, ceftriaxone, and azithromycin were started empirically. The day after admission he was transferred to the intensive care unit for tachypnea and respiratory distress and was intubated for mechanical ventilation; a portable chest X-ray showed multiple patchy airspace opacities ([Figure 1](#fig1){ref-type="fig"}C). The patient became hypotensive, requiring inotropic support, and developed acute kidney injury and renal failure, requiring dialysis. On April 8, RT-PCR assay of the nasopharyngeal swab specimen collected on April 7 was reported to be positive for MERS-CoV for UpE and ORF1a gene targets.[@bib16] Bacterial cultures of blood, sputum, and urine specimens obtained at admission after antibiotic administration were negative. On April 9, he was given 100 mg hydrocortisone intravenously every 8 hours and started on nitric oxide at 16 ppm. The patient\'s condition continued to deteriorate, and he died April 10.Figure 1CXR images. **A:** CXR at initial ED visit shows small left-sided opacity. **B:** CXR at second ED visit, with increase of left-sided opacity. **C:** Portable CXR 1 day after admission with substantial progression of the opacity. CXR, chest X-ray; ED, emergency department.

Autopsy {#sec2.2}
-------

The body was kept refrigerated at 4°C, and an autopsy was performed 10 days after death. Notable findings included massive pleural effusion (5 L), substantial pericardial effusion (150 mL), and abdominal effusion; edematous and consolidated lungs; and generalized congestion.

Histopathology, Immunohistochemistry, and Electron Microscopy {#sec2.3}
-------------------------------------------------------------

The predominant pulmonary histologic pattern was exudative-phase diffuse alveolar damage with denuding of bronchiolar epithelium, prominent hyaline membranes, alveolar fibrin deposits, type 2 pneumocyte hyperplasia, rare multinucleated syncytial cells, and alveolar septa involved by edema and lymphocytes with fewer plasma cells, neutrophils, and macrophages ([Figure 2](#fig2){ref-type="fig"} , A--C). Dispersed foci of necrotic debris were seen both subpleurally and within alveoli. No viral inclusions were seen, and moderate anthracosis was present. All four antibodies (1510/1513, 1511, 1512, and 1514) highlighted multiple foci of MERS-CoV antigens, predominantly localized within the cytoplasm of pneumocytes and syncytial cells ([Figure 2](#fig2){ref-type="fig"}, D--F). Sections of trachea and bronchi showed mild-to-moderate lymphocytic mucosal and submucosal inflammation with a few neutrophils and plasma cells ([Figure 2](#fig2){ref-type="fig"}G). Occasional clusters of noninvasive and extracellular candida yeast and hyphae were seen in septa, alveolar spaces, and overlying respiratory epithelium, suggesting postmortem overgrowth. Bronchial submucosal glands were focally necrotic ([Figure 2](#fig2){ref-type="fig"}H). Immunostaining for MERS-CoV antigens was identified in both unremarkable and necrotic bronchial submucosal glands ([Figure 2](#fig2){ref-type="fig"}I).Figure 2Histopathology of lung from MERS-CoV patient. **A:** Pulmonary edema. **B:** Diffuse alveolar damage, including prominent hyaline membrane formation (**arrow**). **C:** Alveolar fibrin deposits, type 2 pneumocyte hyperplasia, and thickened alveolar septa involved by edema and a mixed inflammatory infiltrate. **D**--**F:** Immunostaining of MERS-CoV antigen in pneumocytes (Ab 1511; **D**, **arrow**), a multinucleated syncytial cell (Ab 1511; **E**, **arrow**), and a binucleated cell (Ab 1514; **F**, **arrow**). **G:** Moderate lymphocytic inflammation of the submucosal glands. **H:** Magnified from the **boxed area** in **G.** Submucosal glands with focal areas of necrosis (**arrow**). **I:** Immunostaining of MERS-CoV antigen in necrotic foci of submucosal glands (**arrow**; Ab 1512). Original magnification: ×5 (**A**); ×20 (**B**--**D**); ×75 (**E**); ×100 (**F**); ×10 (**G**); ×40 (**H**); ×63 (**I**). Ab, antibody; MERS-CoV, Middle East respiratory syndrome coronavirus.

Multiple double immunostaining immunoassays were performed to assess for colocalization of MERS-CoV and cells labeling for cytokeratin, CD68, surfactant, and DPP4. Double staining with cytokeratin confirmed the presence of viral antigens within pneumocytes and epithelial syncytial cells, whereas double staining with CD68 showed two distinct populations with no colocalization of MERS-CoV and macrophages ([Figure 3](#fig3){ref-type="fig"} , A and B). Surfactant double staining revealed type 2 pneumocytes and syncytial cells with intracytoplasmic viral antigens ([Figure 3](#fig3){ref-type="fig"}C). DPP4 antigens were detected in pneumocytes, syncytial cells, mononuclear leukocytes, and vascular endothelium, although colocalization of MERS-CoV and DPP4 was observed in scattered pneumocytes and syncytial cells ([Figure 3](#fig3){ref-type="fig"}D). Electron microscopy showed infected and degenerated pneumocytes encased between hyaline membranes, composed of fibrin and basement membranes ([Figure 3](#fig3){ref-type="fig"}E). Clusters or individualized, predominately spherical, 50 to 150 nm in diameter, viral particles were observed in membrane-bound vesicles ([Figure 3](#fig3){ref-type="fig"}F).Figure 3Immunohistochemical and ultrastructural localization of MERS-CoV and associated histologic findings. **A:** MERS-CoV and cytokeratin antigens in pneumocytes (**arrow**); red stain, MERS-CoV; brown stain, cytokeratin. **B:** MERS-CoV antigens in pneumocytes (**arrowhead**) and CD68 antigens in macrophages (**arrow**); red stain, CD68; brown stain, MERS-CoV. **C:** MERS-CoV and surfactant antigens in type 2 pneumocytes (**arrow**); red stain, surfactant; brown stain, MERS-CoV. **D:** MERS-CoV and DPP4 in pneumocytes (**arrow**); red stain, DPP4; brown stain, MERS-CoV. **E:** Fragmented pneumocyte infected with MERS-CoV, hyaline membrane (**arrowhead**) present. **F:** Magnified from the **boxed area** in **E**. MERS-CoV virions dispersed as single particles (**arrow**) or in clusters within membrane-bound vesicles (**arrowhead**). Spherical and pleomorphic particles ranged in size from 50 to 150 nm diameter. Scale bars: 2 μm (**E**); 500 nm (**F**). Original magnification: ×100 (**A** and **C**); ×63 (**B**); ×75 (**D**). DPP4, dipeptidyl peptidase 4; MERS-CoV, Middle East respiratory syndrome coronavirus.

The kidney showed increased globally sclerotic glomeruli (5% to 10% of glomeruli), thickened Bowman capsules, severe atherosclerosis and hyaline arteriolosclerosis, patchy interstitial inflammation, and intratubular proteinaceous and granular casts. Diminished lymphoid follicles and a robust interfollicular proliferation of pleomorphic immunoblasts intermixed with a polymorphous population of reactive lymphocytes were seen in multiple lymph nodes; the spleen also contained numerous immunoblasts and reactive lymphocytes. The bone marrow was normocellular with maturing trilineage hematopoiesis and left-shifted granulopoiesis. The heart revealed diffuse myocyte hypertrophy, moderate coronary atherosclerosis, and patchy fibrosis. Moderate steatosis, scattered calcifications, and mild portal tract and lobular lymphocytic inflammation were identified in the liver. The sections of the cerebrum and cerebellum were unremarkable. MERS-CoV IHC was negative in multiple specimens from different organs, including kidney, liver, spleen, several lymph nodes, bone marrow, small intestine, and colon.

Overall the histology was well-preserved; although the sections of brain showed minimal-to-mild autolysis and kidney showed moderate autolysis.

Molecular Assays {#sec2.4}
----------------

The genome sequence is similar (\>99%) to other known MERS-CoVs and clustered closely with camel-derived MERS-CoV strains (KJ650295 to KJ650297) obtained in Al-Hasa, Saudi Arabia, in 2013, suggesting recent origin in camels, although the patient had no known camel exposures. As indicated from the phylogenetic tree ([Supplemental Figure S1](#appsec1){ref-type="sec"}), the sequences from this case and close contacts cluster most closely in the same clade, further supporting their transmission link between these cases.

Discussion {#sec3}
==========

This report provides invaluable insights as the first description in the published literature of the clinicopathologic, IHC, and ultrastructural findings of a fatal case of MERS-CoV infection. The histopathologic pattern observed in the lungs was diffuse alveolar damage. MERS-CoV IHC and double staining techniques showed viral antigens were predominantly localized to type 2 pneumocytes and epithelial syncytial cells. Although the pathogenesis of severe and fatal MERS-CoV infection is unknown, these postmortem findings provide critical insights, including evidence that pneumocytes are important targets, suggesting that direct cytopathic effects contribute to MERS-CoV respiratory symptoms. An *ex vivo* study that examined MERS-CoV--infected human lung tissue found evidence of pneumocyte damage by electron microscopy, including detachment of type 2 pneumocytes, and membrane blebbing, suggestive of apoptosis.[@bib17] However, IHC staining for MERS-CoV was patchy, implying that other causes such as immune dysfunction may be relevant. Acute renal failure is commonly observed in critically ill MERS-CoV patients[@bib7], [@bib8], [@bib9], [@bib18] and MERS-CoV RNA was detected in urine[@bib18], [@bib19]; however, no evidence of extrapulmonary MERS-CoV dissemination was observed, suggesting that acute renal failure in this patient was not caused by direct renal infection but likely by other factors, such as hypoperfusion or cytokine dysregulation. The presence of MERS-CoV antigens in submucosal glands provides a mechanism by which the virus enters respiratory secretions and becomes transmissible.

The pathologic features of MERS-CoV are shared by other similar respiratory illnesses, such as severe acute respiratory syndrome (SARS)-CoV. Several reports that evaluated fatal cases of SARS-CoV describe diffuse alveolar damage in various stages as the most characteristic feature,[@bib20] with IHC staining of SARS-CoV antigen primarily in alveolar epithelial cells.[@bib20] Syncytial cells may also be seen with other coronavirus infections, including SARS-CoV and paramyxovirus infections.[@bib20] MERS-CoV entry is mediated by DPP4, which is expressed throughout the lower respiratory tract[@bib17] but also numerous other organs, including the kidney.[@bib10] Double staining with MERS-CoV and DPP4 IHC was seen in pneumocytes and syncytial cells, consistent with the identification of these cells as targets of MERS-CoV infection. In addition, *ex vivo* models have detected MERS-CoV antigen in bronchial epithelial cells, pneumocytes, and endothelium and DPP4 in bronchiolar epithelium, endothelium, pneumocytes, and alveolar macrophages,[@bib17], [@bib21] correlating with our findings. In contrast, the functional receptor for SARS-CoV is angiotensin-converting enzyme 2.[@bib22] Similar to DDP4, angiotensin-converting enzyme 2 has a broad distribution, with heavy expression in alveolar epithelial cells, enterocytes, and endothelial cells.[@bib23] Although evidence shows that SARS-CoV also infects type 2 pneumocytes,[@bib24], [@bib25] SARS-CoV was detected in several extrapulmonary sites by *in situ* hybridization and electron microscopy, including circulating lymphocytes, lymphoid tissues, renal distal tubules, and small intestinal mucosa.[@bib26] Because MERS-CoV RNA was detected in blood,[@bib19] and DPP4 is widely distributed in different tissues,[@bib10] extrapulmonary dissemination could be possible, but we did not detect any evidence of MERS-CoV spread outside the respiratory tract.

Pulmonary findings of consolidation, diffuse alveolar damage, and pleural effusions with no evidence of bacterial pneumonia are consistent with the clinical features reported in other critically ill adults with MERS-CoV infection.[@bib7], [@bib8], [@bib9] Pathologic evidence of several chronic diseases in this patient, including myocardial fibrosis, atherosclerosis, and hepatic steatosis, correlates with reports of individuals with underlying comorbidities, such as end-stage renal disease, diabetes mellitus, hypertension, or cardiac disease, having an increased risk of developing severe MERS-CoV infection.[@bib4], [@bib7] The impact of low-dose oral prednisolone before admission and intravenous hydrocortisone on the clinical course and fatal outcome of this MERS-CoV patient is unknown. Follicular depletion in lymph nodes, consistent with corticosteroid use, was noted, and no bacterial coinfections were identified. The hydrocortisone dosing of 100 mg every 8 hours in the intensive care unit before death was higher than recommended for refractory septic shock by the Surviving Sepsis Campaign guidance,[@bib27] but the patient only received a few doses. A systematic review of high-dose corticosteroids for treatment of SARS-CoV reported evidence of harm without survival benefit.[@bib28] In patients with influenza A(H1N1)pdm09 virus infection, corticosteroid treatment was associated with increased mortality,[@bib29] although further studies are needed. Therefore, until further evidence is available, high-dose corticosteroid treatment for MERS-CoV pulmonary disease should be avoided.[@bib30] Current clinical management of MERS-CoV patients is based on supportive care of complications and adherence to recommended infection prevention and control measures (CDC, [*http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html*](http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html){#intref0025}, last accessed October 9, 2015).

Our findings provide invaluable and unprecedented insights into the histologic changes, pathogenesis, and viral dissemination of MERS-CoV in humans. Further studies, including additional postmortem examinations, evaluation of the host immune response, and identification of sites of viral replication, are necessary to strengthen knowledge on pathogenesis, transmission patterns, and effective treatment strategies for optimal clinical management and infection control practices.

Supplemental Data {#appsec1}
=================

Supplemental Figure S1Phylogenetic analysis of the Abu Dhabi_UAE_8\_2014 sequence. The sequence alignment was generated with 76 nearly complete genome sequences published in GenBank (excluding identical sequences). The Abu Dhabi_UAE_8\_2014 discussed in this study is noted by **red solid circle** and the other cases from the UAE cluster are noted by **black solid circle**s. The camel MERS-CoV sequences are labeled with a **camel symbol**. Posterior probabilities are shown for nodes with a support \>0.8. The scale bar indicates the genetic distance, in substitutions/site. Supplemental Table S1
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[^1]: Ab, antibody; AR, antigen retrieval; DPP4, dipeptidyl peptidase 4; DVD, Division of Viral Diseases (CDC); EMC S, spike protein of human coronavirus Erasmus Medical Center; Envision Doublestain, Envision G/2 Double Stain System, Rabbit/Mouse (DAB + Permanent Red); HKU5.2 N, bat coronavirus HKU5.2 nucleoprotein; HMAF, hyperimmune mouse ascitic fluid; Klear, Klear Human AP-Polymer Detection Kit with GBI Permanent Red Chromogen; MAB, monoclonal antibody; MERS-CoV, Middle East respiratory syndrome coronavirus; PK, proteinase K; UNC, University of North Carolina; UVLP, UltraVision Labeled Polymer Detection Kit.
